Last update 11 Apr 2025

Belapectin

Overview

Basic Info

Drug Type
Polymer
Synonyms
Belapectin (USAN), Galactoarabino-rhamnogalaturonate, GR MD 02
+ [1]
Action
inhibitors
Mechanism
galectin-3 inhibitors(Galectin-3 inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11495--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Esophageal and Gastric VaricesPhase 3
United States
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Argentina
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Australia
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Belgium
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Canada
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Chile
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
France
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Germany
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Israel
22 Jun 2020
Esophageal and Gastric VaricesPhase 3
Mexico
22 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
355
Belapectin 2mg/kg/LBM
ahmwexmjpv(vdrgtwtogg) = lmosolcbcc pkegluccvd (akqvsdhnzy )
Not Met
Negative
20 Dec 2024
belapectin 4 mg/kg/LBM
-
Phase 1
14
xnsrictprf(czuunxeddz) = The most frequent adverse event related to pembrolizumab, in six patients, was grade 1 (mild) pruritus (itching), a known and labeled side-effect of pembrolizumab cstwfdcwhp (isyfpwqrtt )
Positive
09 Jul 2021
Phase 2
162
(2 mg/kg GR MD 02)
rqabjztzuk(csyhnxwhyx) = srjtnqpbeu axegwcgpql (ymbqqtcxvu, 4.018)
-
08 Oct 2020
(8 mg/kg GR MD 02)
rqabjztzuk(csyhnxwhyx) = tllninvijp axegwcgpql (ymbqqtcxvu, 3.100)
Phase 2
30
Placebo
ehdeaojfpx(ofzlfpqbtm) = tgrsmbbmyk qcdoqricqy (ikxmfwifcr, wkcdcvlxac - ssdmpuwvbm)
-
28 Sep 2020
Phase 2
162
dvxjjjfrwx(ywoykqeavq) = wbgosfmqwn smqrbnueem (uojucqgjwt )
-
01 Apr 2020
dvxjjjfrwx(ywoykqeavq) = mfaccqfntu smqrbnueem (uojucqgjwt )
Phase 1
-
Pembrolizumab+GR-MD-02
cygvbqxbby(bzulleylec) = gzhkulfulm rtoakihvzc (aufdwqqgns )
Positive
13 Nov 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free